树突状细胞联合共培养细胞因子诱导的杀伤细胞治疗晚期胃癌临床疗效观察  

Clinical Efficiency Observation of Dendritic Cells and Cytokine-induced Killer Cells Combination Therapy on Advanced Gastric Cancer Patients

作　　者：刘晓玲[1] 董猛[1] 郭红月[1] 唐毅玲[1] 韩景智[1] 崔东晖[1] 

机构地区：[1]河北省沧州中西医结合医院外一科,沧州061001

出　　处：《中国中西医结合外科杂志》2016年第2期124-127,共4页Chinese Journal of Surgery of Integrated Traditional and Western Medicine

摘　　要：目的:探讨树突状细胞(DC)共培养细胞因子诱导的杀伤细胞(CIK)联合化疗治疗晚期胃癌的疗效与安全性。方法:选取66例晚期胃癌患者,随机分为观察组和对照组,每组33例患者,观察组化疗4周期后予DC-CIK生物治疗,对照组常规化疗,观察治疗前后外周血T淋巴细胞亚群、血清肿瘤标志物的改变及临床疗效,记录不良反应。结果:观察组1个月后胃癌患者外周血CD3^+、CD4^+、CD8^+、CD4^+/CD8^+比例均有不同程度提高(P<0.05)。观察组血清肿瘤标志物CEA在治疗后1个月为(11.36±2.62)ng/m L,而对照组为(22.16±13.45)ng/m L,观察组CEA水平较对照组明显下降(P<0.05)。客观缓解率15.2%,疾病控制率33.3%。结论:DC-CIK细胞联合化疗晚期胃癌,可延缓疾病进展,改善患者免疫功能,是安全、有效的治疗方法。ObjectiveTo investigate the safety and clinical effects of dendritic cells（DCs）co-culturedwith cytokine-induced killer cells（CIK）combined with chemotherapy on patients with advanced gastric cancer.MethodsSixty-six patients with advanced gastric cancer were divided into two groups randomly,33 pa-tients in each group.The patients in the observation group were treated with DC-CIK after four cycle chemo-therapy,while the patients in the control group were treated with chemotherapy only.Tlymphocyte subtypes andserum tumor markers were compared between the two groups,The clinical effects were analysed and the safetywas observed.ResultsThe ratios of CD3^＋,CD4^＋,CD8^＋and CD4^＋/CD8^＋in peripheral blood of the patientswere increased after one month treatment（P〈0.05）.The serum tumor marker CEA was found（11.36±2.62）ng/m L in the observation group,and（22.16±13.45）ng/m L in the control group after one month treatment.CEA inthe observation group was decreased obviously as compared with the control group（P〈0.05）.The objective re-sponse rate was 15.2%,and the disease control rate was 33.3%.ConclusionDC-CIK cells combined withchemotherapy can prolong the progression of advanced gastric cancer,by enhancing the autoimmune function,so as a safe and effective treatment.

关 键 词：树突状细胞 细胞因子诱导杀伤细胞 化疗 进展期胃癌 

分 类 号：R735.2[医药卫生—肿瘤]